Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis
Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman
Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman
View: Text | PDF
Research Article Metabolism

HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis

  • Text
  • PDF
Abstract

Carbohydrate response element–binding protein (ChREBP) is a carbohydrate-sensing transcription factor that regulates both adaptive and maladaptive genomic responses in coordination of systemic fuel homeostasis. Genetic variants in the ChREBP locus associate with diverse metabolic traits in humans, including circulating lipids. To identify novel ChREBP-regulated hepatokines that contribute to its systemic metabolic effects, we integrated ChREBP ChIP-Seq analysis in mouse liver with human genetic and genomic data for lipid traits and identified hepatocyte growth factor activator (HGFAC) as a promising ChREBP-regulated candidate in mice and humans. HGFAC is a protease that activates the pleiotropic hormone hepatocyte growth factor. We demonstrate that HGFAC-KO mice had phenotypes concordant with putative loss-of-function variants in human HGFAC. Moreover, in gain- and loss-of-function genetic mouse models, we demonstrate that HGFAC enhanced lipid and glucose homeostasis, which may be mediated in part through actions to activate hepatic PPARγ activity. Together, our studies show that ChREBP mediated an adaptive response to overnutrition via activation of HGFAC in the liver to preserve glucose and lipid homeostasis.

Authors

Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman

×

Figure 3

The phenotype in HGFAC-KO mice recapitulates the phenotype of a putative loss-of-function variant in human HGFAC.

Options: View larger image (or click on image) Download as PowerPoint
The phenotype in HGFAC-KO mice recapitulates the phenotype of a putative...
(A) Schematic depiction of Hgfac gene and the deleted region in red; FWD and REV indicate the positions of forward and reverse primers, respectively, used in genomic PCR shown in (B) confirming the deletion of an 857 bp region in the Hgfac gene. (C) Representative immunoblot of circulating HGFAC in control (wild-type, littermate control) and KO (HGFAC KO) plasma. (D) Hepatic Hgfac mRNA levels measured by qPCR in control and HGFAC-KO mice (n = 7–9/group). (E) Immunoblot and quantification of phosphorylated c-MET in HepG2 cells treated with activated sera of control and HGFAC-KO mice (n = 3/condition). (F) Forest plot of phenotypes associated with the rs3748034 putative loss-of-function coding variant in human HGFAC. (G) Quantification of plasma triglyceride and cholesterol levels in ad libitum chow-fed male control and HGFAC-KO mice (n = 8–13/group), (H) plasma albumin concentrations in male control and HGFAC-KO mice (n = 11–17/group), and plasma platelet levels in male control and HGFAC-KO mice (n = 9–17/group). Data represent means ± SEM. Statistics were assessed by 2-tailed unpaired t test, *P < 0.05; or 1-way ANOVA with Holm-Šídák multiple comparisons test between groups, &P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts